Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
In pharmaceutical development, significant effort is made to minimize the carcinogenic potential of new drug substances (NDS). This involves appropriate genotoxicity and carcinogenicity testing of the NDS, and understanding the genotoxic potential of its impurities. Current available guidance recommends the use of the threshold of toxicological concern (TTC) for a single impurity where mutagenicity but no carcinogenicity information exists. Despite best efforts, the presence of more than one genotoxic impurity in an NDS may occur at trace levels. This paper repeats the analysis performed by others for a single genotoxic compound, but also uses statistical simulations to assess the impact on cancer risk for a mixture of genotoxic compounds. In summary, with the addition of multiple impurities all controlled to the TTC, an increase in cancer risk was observed. This increase is relatively small when considering the conservative assumptions of the TTC. If structurally similar compounds had an assumed strong correlation (+/-10-fold from the first randomly selected impurity) in cancer potency, the resulting cancer risk was not negatively impacted. Findings based on probabilistic analysis here can be very useful in making appropriate decisions about risk management of multiple genotoxic impurities measured in the final drug substance.
Eli Lilly and Company, Lilly Research Laboratories, 2001 W. Main Street, Greenfield, IN 46140, USA. jpbercu@lilly.com
Joel P
JP
Bercu
Wherly P
WP
Hoffman
Cindy
C
Lee
Daniel K
DK
Ness
D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000032:analysis* / Q000633:toxicity; D003257:Consumer Product Safety; D004340:Drug Contamination; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D051379:Mice; D009152:Mutagenicity Tests; D009153:Mutagens / Q000032:analysis* / Q000633:toxicity; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D051381:Rats; D018570:Risk Assessment
D002273:Carcinogens; D009153:Mutagens; D004364:Pharmaceutical Preparations